Form 4: Pulmonx Director Glendon E. French III Sells Shares Under 10b5-1 Trading Plan

Director Glendon E. French III of Pulmonx Corp sold a portion of his holdings in common stock on February 20, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 20, 2025, Glendon E. French III, a director of Pulmonx Corp, sold shares of common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on June 10, 2024.
• A total of 43,036 shares were sold at a weighted average price of $8.14, with individual prices ranging from $7.60 to $8.59.
• An additional 12,417 shares were sold at a weighted average price of $8.76, with individual prices ranging from $8.60 to $9.11.
• Following these transactions, French directly owns 1,011,974 shares of Pulmonx Corp.
• The sales were reported on a Form 4 filing with the Securities and Exchange Commission.

Sentiment

Score: 5

Explanation: The document reports routine stock sales by a director under a pre-arranged trading plan, which is neither particularly positive nor negative. It's a neutral event.

Industry Context

Sales by company insiders are a common occurrence and are often viewed in the context of overall market conditions and company performance. Rule 10b5-1 plans are designed to allow insiders to sell shares without being accused of acting on non-public information.

Stakeholder Impact

• The share sales could have a minor impact on shareholder sentiment, depending on how the market interprets the director's actions.

Key Dates

Keywords

Pulmonx Corp, Glendon E. French III, Form 4, Share Sale, Rule 10b5-1, Director, LUNG